EP1210081A2 - Combinaison d'agents actifs comprenant de la clonidine - Google Patents

Combinaison d'agents actifs comprenant de la clonidine

Info

Publication number
EP1210081A2
EP1210081A2 EP00951485A EP00951485A EP1210081A2 EP 1210081 A2 EP1210081 A2 EP 1210081A2 EP 00951485 A EP00951485 A EP 00951485A EP 00951485 A EP00951485 A EP 00951485A EP 1210081 A2 EP1210081 A2 EP 1210081A2
Authority
EP
European Patent Office
Prior art keywords
active ingredient
combination according
ingredient combination
clonidine
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00951485A
Other languages
German (de)
English (en)
Inventor
Hans-Michael Brecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1210081A2 publication Critical patent/EP1210081A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Definitions

  • the invention relates to a new active ingredient combination of pramipexole and clonidine for the more effective treatment of restless leg syndrome (RLS).
  • RLS restless leg syndrome
  • Restless Leg Syndrome is a neurological disorder that mainly manifests itself in leg disorders such as tingling, pulling, tearing, itching, burning, cramps or pain and triggers the irresistible urge to move. These disorders frequently occur when the person concerned is resting. Especially at night when sleeping, these emotional disorders and the consequent urge to move lead to restlessness and sleep disorders.
  • the RLS occurs at all ages, with the frequency increasing in older age. The prevalence in the general population is around 5%. Because of the characteristics of the symptoms, RLS is one of the most common causes of sleep disorders. In 20-40 year olds, the RLS in 7%, in 40-60 year olds in 18% and in those over 60 in 33% cause sleep-wax disorders.
  • L-DOPA levodopa
  • the dopamine agonists examined include: bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexole and ropinirole. All of these dopamine agonists were found to be effective. There are no study results on long-term therapy with dopamine agonists, so that the question of the loss of effectiveness after long-term use (tachyphylaxis) cannot yet be answered.
  • the disadvantage of dopamine agonists is the occurrence of side effects such as nausea, vomiting, dizziness, hypotension, constipation, insomnia, which usually occur initially and depending on the dose.
  • Benzodiazepines and opiates are also effective in RLS. However, due to the risk of dependency and the development of tolerance, these substances are only available for therapy to a limited extent.
  • Carbamazepine has only been tested in a few partially open studies in the indication RLS. It only leads to partial freedom from symptoms and is currently not considered a suitable means of treating the RLS.
  • the present invention therefore relates to a combination of active substances for the treatment of restless leg syndrome, which contains clonidine or one of its pharmacologically acceptable salts and pramipexole or a corresponding pharmacologically acceptable salt thereof and overcomes the disadvantages of the monotherapies known from the prior art.
  • the advantage of the invention is, inter alia, that the combined administration of clonidine influences the action of the dopamine agonist pramipexole synergistically (or vice versa) in the sense of an increase in activity, so that even low doses of both active ingredients are sufficient to improve the patient's condition without that intolerable side effects occur.
  • the combined administration of pramipexole with clonidine also leads to better responsiveness and a higher responder rate in patients with RLS.
  • the extent to which the additional administration of clonidine can cancel out any tachyphylaxis that may occur with dopaminergic therapeutic agents is not yet known, but is suspected.
  • the two active ingredients clonidine and pramipexole are preferably used as the hydrochloride.
  • other pharmacologically acceptable salts or the neutral compounds can also be used.
  • the active ingredient combination according to the invention it is not necessary for both active ingredients to be in the form of a salt, especially same salt (for example as hydrochloride) can be used.
  • the two active ingredients can be used both as neutral compounds, as two different salts or as a combination of a salt of one active ingredient and the neutral other
  • Active ingredient can be used.
  • the active substance combination according to the invention can be formulated in accordance with the conventional pharmaceutical processes known from the prior art so that it can be administered orally, spinally, anal, intravenously, by inhalation, subcutaneously or transdermally. Oral and transdermal application forms are preferred.
  • Oral administration can take the form of a tablet, powder, powder in a capsule (e.g. hard gelatin capsule), solution or suspension.
  • the active substance combination according to the invention is given as a solution.
  • the anal application takes place via suppositories.
  • the active ingredient combination can be in the form of a powder, as an aqueous or aqueous-ethanolic solution or by means of a propellant gas formulation.
  • the active ingredient can be applied to the skin either as an ointment or cream, but is preferably administered via a plaster.
  • the active ingredient or combination of active ingredients can either be delivered directly to the outer skin layer or it can be embedded as a solution or as a gel, e.g. in a polymer matrix, using a transdermal patch, via microneedles or microcuts that penetrate the stratum corneum of the skin released directly into the deeper layers of skin.
  • a transdermal patch with micro-cutting edges or micro-spikes is disclosed, for example, in patent application WO 97/03718.
  • Patent application WO 91/07998 describes a method by means of which active ingredients can be applied transdermally in an improved manner by adjusting a certain pH of the skin.
  • the delivery is controlled electronically, possibly under the control of the blood plasma level by sensors or microsensors, which can be integrated in the plaster or are communicatively connected to it, so that the blood plasma level can be set in a targeted manner according to the individual need and consequently a constant delivery is not mandatory is required.
  • the two active ingredients can be present in a separate formulation (for example, each in a capsule or in each case as a tablet), in a single formulation, but separated from one another (for example in a capsule with two chambers), or they are in a single formulation mixed before (eg in the form of a tablet or in a capsule with only one chamber).
  • the two active ingredients are each formulated independently of one another, the two formulations can be offered in the form of a combination pack (kit).
  • the two substances are administered via the same route of administration, but combinations of formulations in which the two active compounds are administered via separate routes of administration can also be used.
  • clonidine can be administered orally while pramipexole is transdermal, e.g. is applied over the transdermal patch described above.
  • preferred formulations are those in which the two active compounds are administered via the same route of administration.
  • the two active ingredients are advantageously formulated together in one application form.
  • the two active substances can either be given in a separate patch, in a common patch, but both active substances are stored separately within the patch, or they are present as a mixture in one patch.
  • the active substance formulation according to the invention is prepared in accordance with the methods known from the prior art and can accordingly contain the formulation constituents which are known in the relevant field.
  • it can contain other pharmacologically active substances or cosmetic additives.
  • an almost simultaneous or overlapping intake or administration is preferred.
  • oral administration for example, within 1 hour, preferably within 15 minutes.
  • the amount of the clonidine or the pharmacologically acceptable salt of the formulation according to the invention per single dose, based on clonidine, corresponds to an oral administration of 0.01 to 1.0 mg, preferably 0.05 to 0.5 mg and very particularly preferably 0.075 to 0 , 3 mg.
  • the amount of pramipexole or its pharmacologically acceptable salt corresponds to an oral dose of 0.05-2 mg, preferably 0.08-1.0 mg, particularly preferably 0.088-0.7 mg, per single dose, based on the neutral compound.
  • the exact amount of the active ingredients can be determined simply
  • both patients were treated with pramipexole, namely 0.088 mg two hours before bedtime.
  • the daily dose had to be increased to 0.36 mg at weekly intervals, in the patient to 0.27 mg.
  • the symptoms had improved in both patients, but there was no difference between the two patients and the previous therapy.
  • both patients were treated with a combination of 0.088 mg pramipexole and 0.075 mg clonidine. After the first night, both patients reported a clear alleviation of the symptoms. After 7 days, the
  • Pramipexole and clonidine showed in both patients by the end of the

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une combinaison d'agents actifs constituée de clonidine et de pramipexole qui permet de traiter le syndrome des jambes sans repos.
EP00951485A 1999-08-19 2000-08-09 Combinaison d'agents actifs comprenant de la clonidine Withdrawn EP1210081A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19938825A DE19938825A1 (de) 1999-08-19 1999-08-19 Wirkstoffkombination mit Clonidin
DE19938825 1999-08-19
PCT/EP2000/007718 WO2001013902A2 (fr) 1999-08-19 2000-08-09 Combinaison d'agents actifs comprenant de la clonidine

Publications (1)

Publication Number Publication Date
EP1210081A2 true EP1210081A2 (fr) 2002-06-05

Family

ID=7918574

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00951485A Withdrawn EP1210081A2 (fr) 1999-08-19 2000-08-09 Combinaison d'agents actifs comprenant de la clonidine

Country Status (19)

Country Link
US (1) US20020010201A1 (fr)
EP (1) EP1210081A2 (fr)
JP (1) JP2003507420A (fr)
KR (1) KR20020060163A (fr)
AR (1) AR025330A1 (fr)
AU (1) AU6440600A (fr)
BR (1) BR0013353A (fr)
CA (1) CA2376606A1 (fr)
CO (1) CO5200840A1 (fr)
CZ (1) CZ2002515A3 (fr)
DE (1) DE19938825A1 (fr)
IL (1) IL147741A0 (fr)
MX (1) MXPA02001138A (fr)
NO (1) NO20020793L (fr)
PE (1) PE20010642A1 (fr)
PL (1) PL353358A1 (fr)
TR (1) TR200200449T2 (fr)
UY (1) UY26293A1 (fr)
WO (1) WO2001013902A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP2305252A1 (fr) 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Utilisation de pramipexole pour traiter la sclérose latérale amyotrophique
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
AU2003262860A1 (en) 2002-08-30 2004-03-19 Kyowa Hakko Kogyo Co., Ltd. Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
DK1426049T3 (da) * 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CA2652251A1 (fr) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions de r(+) et s(-) pramipexole et procedes d'utilisation de celles-ci
WO2008009664A2 (fr) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Traitement de la douleur
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (fr) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthèse de benzothiazole diamines substituées et purifiées du point de vue chiral
EP1987815A1 (fr) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Compositions pharmaceutiques à base d'agonistes dopaminergiques administrables par voie oro-naso-pharyngale pour la prévention et/ou le traitement de membres sans repos
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2013096816A1 (fr) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Synthèse améliorée de composés substitués par amine de 4,5,6,7-tétrahydrobenzothiazole
CA2896055C (fr) * 2012-12-28 2021-02-16 Noven Pharmaceuticals, Inc. Compositions et procedes pour l'administration transdermique d'amphetamine et de clonidine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0113902A2 *

Also Published As

Publication number Publication date
AR025330A1 (es) 2002-11-20
WO2001013902A2 (fr) 2001-03-01
CO5200840A1 (es) 2002-09-27
NO20020793D0 (no) 2002-02-18
PE20010642A1 (es) 2001-06-08
TR200200449T2 (tr) 2002-08-21
MXPA02001138A (es) 2002-10-31
PL353358A1 (en) 2003-11-17
CA2376606A1 (fr) 2001-03-01
AU6440600A (en) 2001-03-19
NO20020793L (no) 2002-02-18
BR0013353A (pt) 2002-04-23
KR20020060163A (ko) 2002-07-16
US20020010201A1 (en) 2002-01-24
CZ2002515A3 (cs) 2002-05-15
WO2001013902A3 (fr) 2001-08-23
IL147741A0 (en) 2002-08-14
DE19938825A1 (de) 2001-04-26
JP2003507420A (ja) 2003-02-25
UY26293A1 (es) 2001-04-30

Similar Documents

Publication Publication Date Title
WO2001013903A2 (fr) Traitement therapeutique du syndrome des jambes sans repos
EP1210081A2 (fr) Combinaison d'agents actifs comprenant de la clonidine
EP1940398A1 (fr) Utilisation de pramipexol pour traiter le syndrome des jambes sans repos (rls) modere a severe
KR19990036073A (ko) 내이질병치료용아다만탄유도체의용도
DE3023588A1 (de) Mittel zum abgewoehnen des rauchens und zum verlieren von uebergewicht
EP1397138B1 (fr) ASSOCIATION DE PRINCIPES ACTIFS (par ex. de la galanthamine ou la désoxypéganine avec de l'acamprosate ou la mémantine) DESTINEE AU TRAITEMENT D'UNE INTOXICATION A DES SUBSTANCES ENTRAINANT UNE DEPENDANCE OU A DES STUPEFIANTS
DE60013466T2 (de) Im mund zerfallende zusammensetzung mit mirtazapin
WO1992011012A1 (fr) Utilisation d'antagonistes des recepteurs de quisqualate pour le traitement de la maladie de parkinson
DE10163667B4 (de) Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE19519056A1 (de) Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation
WO2008010768A1 (fr) Méthode de traitement et de diagnostic du syndrome des jambes sans repos et de mouvements involontaires des membres pendant le sommeil et moyen pour la mise en oeuvre de ladite méthode
WO2001052854A1 (fr) Antagonistes du recepteur nk1 utilises pour le traitement du syndrome des jambes sans repos
DE10293600B4 (de) Rezeptoradaptierter Nikotinentzug durch anticholinerge und noradrenerge Blockade
DE10318714B4 (de) Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
CA2102187C (fr) Utilisation d'atipamezole pour le traitement de l'impuissance chez l'homme
EP1524982A1 (fr) Medicament et procede pour limiter la consommation d'alcool et/ou de tabac
IE83685B1 (en) Use of atipamezole
AT504700A1 (de) Behandlung von angstzuständen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020319

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20020319;LV PAYMENT 20020319;MK;RO PAYMENT 20020319;SI PAYMENT 20020319

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030303